View in EDS HTML Full Text PDF Full Text

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.

Saved in:
Bibliographic Details
Title: Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Authors: Hong DS; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Butler MO; Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, ON, Canada., Pachynski RK; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States., Sullivan R; Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Kebriaei P; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Boross-Harmer S; Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, ON, Canada., Ghobadi A; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States., Frigault MJ; Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Dumbrava EE; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Sauer A; Adaptimmune LLC, Philadelphia, PA, United States., Brophy F; Adaptimmune LLC, Philadelphia, PA, United States., Navenot JM; Adaptimmune LLC, Philadelphia, PA, United States., Fayngerts S; Adaptimmune LLC, Philadelphia, PA, United States., Wolchinsky Z; Adaptimmune Limited, Abingdon, United Kingdom., Broad R; Adaptimmune Limited, Abingdon, United Kingdom., Batrakou DG; Adaptimmune LLC, Philadelphia, PA, United States., Wang R; Adaptimmune Limited, Abingdon, United Kingdom., Solis LM; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Duose DY; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Sanderson JP; Adaptimmune Limited, Abingdon, United Kingdom., Gerry AB; Adaptimmune Limited, Abingdon, United Kingdom., Marks D; Adaptimmune LLC, Philadelphia, PA, United States., Bai J; Adaptimmune LLC, Philadelphia, PA, United States., Norry E; Adaptimmune LLC, Philadelphia, PA, United States., Fracasso PM; Adaptimmune LLC, Philadelphia, PA, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Mar 18; Vol. 12, pp. 818679. Date of Electronic Publication: 2022 Mar 18 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35372008
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Butler+MO%22">Butler MO</searchLink>; Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Pachynski+RK%22">Pachynski RK</searchLink>; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.<br /><searchLink fieldCode="AU" term="%22Sullivan+R%22">Sullivan R</searchLink>; Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.<br /><searchLink fieldCode="AU" term="%22Kebriaei+P%22">Kebriaei P</searchLink>; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Boross-Harmer+S%22">Boross-Harmer S</searchLink>; Princess Margaret Hospital Cancer Centre, University of Toronto, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Ghobadi+A%22">Ghobadi A</searchLink>; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States.<br /><searchLink fieldCode="AU" term="%22Frigault+MJ%22">Frigault MJ</searchLink>; Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.<br /><searchLink fieldCode="AU" term="%22Dumbrava+EE%22">Dumbrava EE</searchLink>; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Sauer+A%22">Sauer A</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Brophy+F%22">Brophy F</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Navenot+JM%22">Navenot JM</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Fayngerts+S%22">Fayngerts S</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Wolchinsky+Z%22">Wolchinsky Z</searchLink>; Adaptimmune Limited, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Broad+R%22">Broad R</searchLink>; Adaptimmune Limited, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Batrakou+DG%22">Batrakou DG</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Wang+R%22">Wang R</searchLink>; Adaptimmune Limited, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Solis+LM%22">Solis LM</searchLink>; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Duose+DY%22">Duose DY</searchLink>; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Sanderson+JP%22">Sanderson JP</searchLink>; Adaptimmune Limited, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Gerry+AB%22">Gerry AB</searchLink>; Adaptimmune Limited, Abingdon, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Marks+D%22">Marks D</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Bai+J%22">Bai J</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Norry+E%22">Norry E</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Fracasso+PM%22">Fracasso PM</searchLink>; Adaptimmune LLC, Philadelphia, PA, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2022 Mar 18; Vol. 12, pp. 818679. <i>Date of Electronic Publication: </i>2022 Mar 18 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35372008
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2022.818679
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 818679
    Titles:
      – TitleFull: Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hong DS
      – PersonEntity:
          Name:
            NameFull: Butler MO
      – PersonEntity:
          Name:
            NameFull: Pachynski RK
      – PersonEntity:
          Name:
            NameFull: Sullivan R
      – PersonEntity:
          Name:
            NameFull: Kebriaei P
      – PersonEntity:
          Name:
            NameFull: Boross-Harmer S
      – PersonEntity:
          Name:
            NameFull: Ghobadi A
      – PersonEntity:
          Name:
            NameFull: Frigault MJ
      – PersonEntity:
          Name:
            NameFull: Dumbrava EE
      – PersonEntity:
          Name:
            NameFull: Sauer A
      – PersonEntity:
          Name:
            NameFull: Brophy F
      – PersonEntity:
          Name:
            NameFull: Navenot JM
      – PersonEntity:
          Name:
            NameFull: Fayngerts S
      – PersonEntity:
          Name:
            NameFull: Wolchinsky Z
      – PersonEntity:
          Name:
            NameFull: Broad R
      – PersonEntity:
          Name:
            NameFull: Batrakou DG
      – PersonEntity:
          Name:
            NameFull: Wang R
      – PersonEntity:
          Name:
            NameFull: Solis LM
      – PersonEntity:
          Name:
            NameFull: Duose DY
      – PersonEntity:
          Name:
            NameFull: Sanderson JP
      – PersonEntity:
          Name:
            NameFull: Gerry AB
      – PersonEntity:
          Name:
            NameFull: Marks D
      – PersonEntity:
          Name:
            NameFull: Bai J
      – PersonEntity:
          Name:
            NameFull: Norry E
      – PersonEntity:
          Name:
            NameFull: Fracasso PM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 03
              Text: 2022 Mar 18
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1